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rubles ($209) per extra patient without moderate and severe dis-
ability after 3 months of treatment. CONCLUSION: Betahistine
is an appropriate alternative to cinnarizine for patients with
vertigo.
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OBJECTIVE: To assess the cost-effectiveness of switching from
oral polio vaccine (OPV) to inactivated poliovirus vaccine (IPV),
or to cease polio vaccination in routine immunization services in
South Africa. METHODS: The incremental cost-effectiveness of
three different polio vaccination alternatives was compared to
the current schedule of six doses of OPV: (1) IPV at 2, 4, and 6
months; (2) IPV at 6, 10, 14 weeks and 18 months and (3) ces-
sation of polio vaccination. The costs of introducing IPV in a
separate vial as well as in different combination vaccines were
estimated. Assumptions about IPV vaccine prices were based on
indications from vaccine manufacturers. Treatment costs of polio
and the costs of lost productivity were included. The health
impact of OPV cessation was measured in terms of Vaccine Asso-
ciated Paralytic Paralysis [VAPP] cases and Disability Adjusted
Life Years [DALYs] averted. One-way sensitivity analysis was
performed on the most uncertain variables. RESULTS: The use
of OPV in routine immunization services is projected to result in
2.96 VAPP cases in the 2005 cohort. A switch to IPV will
increase the total vaccine budget by at least 20%. The cost-effec-
tiveness of the different IPV alternatives varies between US$
118,000 and US$594,000 per discounted DALY averted. 3 doses
of IPV in a 10-dose vial is the most cost-effective option. CON-
CLUSION: Due to the risk of VAPP, it has been recognized that
when global polio eradication has been achieved, all countries
must cease the use of OPV if the world is to remain polio-free.
However, at the assumed vaccine prices, IPV does not appear to
be cost-effective in the South African situation. The alternative
of ceasing polio vaccination altogether is more economically
acceptable, but the perceived risks of this alternative could be a
hindrance for its implementation.
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OBJECTIVE: In addition to the costs of treatment and preven-
tion, diseases generate other types of costs that are not always
addressed. The purpose of the present work is to identify
measure and evaluate the costs of informal care for neurological
diseases in Spain. METHODS: The data collected in the Survey
on Disabilities, Impairments, and State of Health (EDDES, for
its initials in Spanish) of the National Institute of Statistics (INE)
was used to estimate these costs. The EDDES is a national survey
that covers all individuals residing in primary family housing. A
total of 79,000 households were selected and information
regarding 290,000 people was collected. We estimate that
423,188 people (1.03% of Spanish population in 2001) suffer
an incapacity caused by a neurological disease: stroke, sclerosis,
dementia (including Alzheimer) and Parkinson. Our estimation
includes only those costs that have to do with informal care; that
is, those caregivers that are not paid for their work. We estimated
the opportunity cost of the time of caregivers, distinguishing if
the caregiver has given up his job or has reduced the total supply
of hours of work. RESULTS: The informal costs estimated range
between 2402 and 2926 millions of euros (at year 2002 prices),
depending on how comorbidity is handled. The estimated costs
of informal care of each neurological disease were: stroke (823
to 1007); dementia (1021 to 1246); Parkinson disease (329 to
401); and multiple sclerosis (229 to 272). The estimated infor-
mal costs represent a %6.3 to %7.7 per cent of the total health
care costs of the Spanish National Health System. We also esti-
mated the informal costs per patient and disease. CONCLU-
SIONS: The cost of informal care in main neurological disorders
is substantial, and if ﬁnanced it could devote a considerable
budget from the overall Spanish Health Care System 
expenditure.
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OBJECTIVES: To identify and summarise the economic evidence
for botulinum toxins in post-stroke spasticity and spasticity asso-
ciated with cerebral palsy. METHODS: Cost-effectiveness and
cost-analysis studies of interventions for treatment of postictal
and cerebral-palsy-related spasticity, in which at least one arm
consists of a botulinum toxin, were considered for inclusion in
the review. Medline, Embase, NHSEED and the proprietary
Allergan Botulinum Database were searched up until February
16, 2004 for relevant studies. Additionally, conference proceed-
ings of seven clinical and pharmacoeconomic organisations 
were hand searched for the period of 2001 to 2004. RESULTS:
One cost-effectiveness (Wallesch 1997), two cost-consequence
(Houltram 2001, Loaiza 2000) and two cost studies (Balkrish-
nan 2002, Radensky 2001) met the criteria for inclusion in 
the review. Wallesch presented the incremental cost per unit
improvement in Ashworth scale, Loaiza presented quality
adjusted life years and Houltram presented Modiﬁed Ashworth
Scale together with several other functional measures. The cost
analyses found that overall treatment costs were lower in treat-
ment plans that included botulinum toxin A (Btx-a). Although
Btx-a increased drug costs by between $750 and $1000 annu-
ally, overall treatment costs were lower due to the reduced hos-
pitalisation and nursing facility admissions associated with Btx-a
treatment. Btx-a treatment was also associated with fewer co-
administered treatments, and resulted in lower treatment costs
than treatment plans that did not include Btx-a. CONCLUSION:
The addition of botulinum toxin to a treatment regimen appears
to be cost neutral. There is a need for cost-effectiveness analyses
using outcome measures with greater external validity than those
identiﬁed in the studies included in the review. A cost-utility
analysis based on clearly derived utilities is required.
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OBJECTIVE: Restless legs syndrome (RLS) is a neurological dis-
order characterised by unpleasant sensations in the legs and an
irresistible urge to move the legs to relieve the discomfort. This
study aims to describe the drug treatment patterns amongst UK
RLS patients during a 12-month period; in this period pharma-
cological therapy was based on “off-label” use of medication.
METHODS: A data base capturing nationally representative
prescribing for patients presenting in general practice (DIN-
LINK) was used to describe treatments received by patients with
a diagnosis of RLS presenting to a GP in the 12 months up to
31st March 2005 (n = 556). This data base covers a population
of about 800,000 patients and about 400 GPs. RESULTS: Annu-
ally, the number of patients with RLS for which they were receiv-
ing drug treatment was estimated to be up to 46 per 100,000
catchment population (up to 66% of the 70 per 100,000 patients
with RLS who annually make contact with a GP). Drug treat-
ments included the following (the percentages of patients receiv-
ing the different types of drug treatments are shown in brackets):
antidepressants (20% of whom 71% received amitriptyline),
anticonvulsants (18% of whom 76% received clonazepam),
quinine (13%), non-narcotic analgesia (13%), dopamine ago-
nists (5%), hypnotics (6%), tranquilisers (4%) NSAIDs (3%)
and L-dopa (4%). CONCLUSIONS: The substantial percentage
of patients receiving some form of analgesia or treatment for
insomnia may be a reﬂection of the limited success of existing
patterns of treatment in controlling symptoms (presumably, clon-
azepam in line with UK guidelines, was used mostly for insom-
nia). A large proportion of RLS patients were given amitriptyline
which can worsen RLS and quinine, a treatment effective only
when cramps co-exist.
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OBJECTIVES: ISPR is a prospective, post-market, surveillance
registry designed to monitor implantable neurological devices.
For each patient enrolled demographics, implant and practice
techniques, and patient reported outcomes are collected and ana-
lyzed to elucidate the etiology of device complications. The goal
is to expand registry centers, based on pre-deﬁned criteria, and
generate data representative of the medical community and its
patients. This registry is a foundation and electronic platform for
outcome registry projects. METHODS: Single and multi-physi-
cian centers follow standard clinical practice and a common reg-
istry protocol. Center activation includes software and protocol
training and IRB approval at each center. Information registered
with the U.S Food and Drug and Administration (FDA) man-
dated Device Registration System (DRS) pre-populates the reg-
istry avoiding redundant data submission, while centers provide
additional information through electronic data capture. Active
surveillance occurs at 6-month intervals with data reporting
required for device or patient events. These event data are elec-
tronically communicated to fulﬁll FDA-mandated event report-
ing regulations, thus creating efﬁciencies for the sponsor and
physician. The potential of selection bias in ISPR is minimized
through 100% eligibility of all implanted devices at each center.
The approach for ISPR center expansion is based on geographic,
specialty, and practice distribution to achieve a representative
sampling of real world experience, effectiveness and safety. A
multidisciplinary advisory board oversees reporting with the goal
of peer reviewed scientiﬁc presentation and publication.
RESULTS: Annual aggregate and center speciﬁc reports are gen-
erated including descriptive statistics and survival curves. CON-
CLSUIONS: The data collected in this registry are representative
of the medical community with generalizability to a broader
patient population. ISPR results may illuminate methods to
improve therapy and guide development, provide insight into the
etiology of events through evaluation beyond what is possible
with passive surveillance, and generate best practices associated
with reduced events and improved outcomes.
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OBJECTIVES: To measure frequency and intensity of diabetic
peripheral neuropathy (DPN) symptoms a 6 item scale was
developed in US English for health care professionals (HCP): the
Neuropathy Total Symptom Score-6 (NTSS-6). Prior to use in an
international study a self-administered (SA) version was devel-
oped and translated into 9 languages. METHODS: The devel-
opment of the SA version involved the establishment of patient
instructions and the comprehension test on 5 US patients with
DPN and 2 diabetologists. The following translation process was
conducted by a specialist in each target country: (1) two forward
translations; (2) back translation; (3) review by a clinician; (4)
comprehension test on 5 subjects with DPN and (5) international
harmonisation. Where translations of the HCP version existed,
an SA version was developed and the accuracy of the transla-
tions checked. RESULTS: The ﬁrst challenge was maintaining
conceptual equivalence between the HCP and SA versions. The
development of the SA version required patients’ understanding
the meaning of the explored symptoms and their level of sever-
ity without clariﬁcation by HCPs. The second challenge was
ﬁnding conceptually equivalent and culturally relevant expres-
sions of the different types of pain. In some instances literal
equivalents for the original symptom existed, but according to
patients did not correspond to the original concept. In other
cases the original did not have a literal equivalent and had to be
paraphrased. CONCLUSIONS: The 9 languages of the NTSS-6
SA were established according to a rigorous development and
translation process to ensure conceptual equivalence and cultural
relevance across languages and ultimately the international com-
parison and pooling of data. Issues encountered during this
process support the advantage of integrating international feed-
back on concepts and wording before ﬁnalizing a scale.
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Different surgical procedures are described to improve hand-
function in tetraplegie either with or without implantation of an
8-channel electrical stimulator. Clinical experience shows that
patients are not always willing to accept these devices despite
their severe functional limitations. This can be explained because
the offered treatment is too demanding. For future clinical appli-
cations and for further technical developments it is necessary to
obtain more insight into the factors that determine willingness
to accept assistive technology. OBJECTIVES: To determine the
